Meta AnalysisID 6408
舒血宁注射液联合依达拉奉治疗脑梗死：一项随机对照试验的系统评价和Meta分析
CRD42022333935
The aim of this systematic review was to assess the effects and safety of SXN injection with edaravone for cerebral infarction.
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Formula: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 6408
- Evidence Id
- 14966
- Core Evidence Id
- 14966
- Source Meta Analysis Id
- 6392
- Herb2 Meta Analysis Id
- HBMA006392
- Crd Id
- CRD42022333935
- Title
- Shuxuening injection with edaravone for cerebral infarction: A systematic review and meta-analysis of randomized controlled trials
- Review Question
- The aim of this systematic review was to assess the effects and safety of SXN injection with edaravone for cerebral infarction.
- Study Type Included
- RCTs of SXN injection plus edavavone in conventional treatment compared with placebo plus edaravone conventional treatment control. RCTs involving SXN injection plus edavarone combined with another therapy versus this therapy alone would also be included. Trials comparing different types of SXN injections plus edaravone were excluded. Besides, trials involving SXN injection plus Chinese medicine compared with Chinese medicine would be excluded.
- Condition Being Studied
- Cerebral infarction is a common cerebrovascular disease. More than 690, 000 adults suffer from this disease each year in the United States. Cerebral infarction can lead to neurological impairment, motor weakness, speech difficulty, visual loss, dizziness, severe headache, and even death. American Heart Association (AHA) and American Stroke Association (ASA) suggest that cerebral infarction can be treated by intravenous recombinant tissue-type plasminogen activator (rtPA), anticoagulants, fibrinolytic agents, antiplatelet agents, and other western therapies. However, any medical therapy may carry more than minimal risk and the treatment of intravenous rtPA is associated with increased rates of intracranial hemorrhage, which may be fatal.
- Participant
- A total of 2076 participants in 19 trials were included and the sample sizes were ranging from 30 to 273. The age of patients ranged from 18 to 87 years. The disease course ranged from 1 hour to 72 hour. Patients with a clinical diagnosis of cerebral infarction and further confirmed by computed tomography (CT) or magnetic resonance imaging (MRI). The subtypes of cerebral infarction would be included as follows: atherosclerotic thrombotic cerebral infarction, cerebral embolism, and lacunar infarction. But there was no limitation on the area and the scope of infarction. The age of patients should be less than 85 years old, whereas the gender has no limitation. Besides, patients with subarachnoid hemorrhage, cerebral hemorrhage, or other hemorrhagic cerebrovascular diseases would be excluded. Moreover, patients suffered from transient ischemic attack, cerebral vascular dementias, hypertensive encephalopathy, stroke-causing tumors, or accompanied by severe heart, liver, and kidney disease would be excluded.
- Animal
- Human Disease Modelled
- Intervention
- RCTs of SXN injection with edaravone plus routine treatment. RCTs of SXN injection combined with edaravone in another therapy would also be included. Trials comparing different types of SXN injections were excluded. Besides, trials involving SXN injection plus Chinese medicine compared with Chinese medicine would be excluded.
- Comparator Control
- RCTs of placebo plus edaravone conventional treatment control. RCTs involving edaravone in another therapy alone would also be included. Trials comparing different types of SXN injections plus edaravone were excluded. Besides, trials involving SXN injection plus Chinese medicine compared with Chinese medicine would be excluded.
- Main Outcome
- The primary outcome was the neurologic deficit measured by National Institutes of Health Stroke Scale (NIHSS). The secondary outcomes were: 1 quality of life measured by Barthel Index (BI) and ADL scores; 2 response rates (proportion of patients improved): cure (neurologic deficit scores reduced rate from 91% to 100%), significantly effective (neurologic deficit scores reduced rate more from 46% to 90%), effective (neurologic deficit scores reduced rate from 18% to 46%), and ineffective (neurologic deficit scores scores reduced rate less than 18%); 3 Fibrinogen (FIB)
- Outcome Measure
- Additional Outcome
- The primary outcome was the neurologic deficit measured by National Institutes of Health Stroke Scale (NIHSS). The secondary outcomes were: 1 quality of life measured by Barthel Index (BI), ADL scores and Fibrinogen (FIB); 2 response rates (proportion of patients improved): cure (neurologic deficit scores reduced rate from 91% to 100%), significantly effective (neurologic deficit scores reduced rate more from 46% to 90%), effective (neurologic deficit scores reduced rate from 18% to 46%), and ineffective (neurologic deficit scores scores reduced rate less than 18%); 3 safety: adverse drug events and reactions caused by DZXX injection during scheduled treatment and follow-up
- Study Method
- Meta-analysis, Systematic review
- Keyword
- Cerebral Infarction; Drugs, Chinese Herbal; Edaravone; Humans; Randomized Controlled Trials as Topic; shuxuening
- Contact
- Jiawei Wang [email protected]
- Organisational Affiliation
- Shandong University of Traditional Chinese Medicine
- Funding Source
- None Grant number(s) <span style=font-size: 14px>State the funder, grant or award number and the date of award</span> None
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2022-05-20
- Registration Date
- 2022-05-30
- Anticipated Start Date
- 2022-04-08
- Anticipated Completion Date
- 2022-06-20
- Title Cn
- 舒血宁注射液联合依达拉奉治疗脑梗死：一项随机对照试验的系统评价和Meta分析
- Title En
- Shuxuening injection with edaravone for cerebral infarction: A systematic review and meta-analysis of randomized controlled trials
- Bilingual Status
- complete